Tag archive


Singapore eDevelopment subsidiary Global BioLife’s 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis

in Pharmaceutical News
Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis

Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis. Tuberculosis is the leading cause of deaths from a single infectious agent, infecting about one quarter of the world’s population. The fragrance was shown to inhibit Mycobacterium tuberculosis (MTB), the causative bacterial agent of tuberculosis. The experiments were performed at ATCC, as a custom service within its High Containment Laboratory under BioSafety Level 3…

Keep Reading

US pharma executives reveal their attitudes to the UK and Brexit

in Pharmaceutical Articles

What will Brexit mean for pharma companies on both sides of the Atlantic? Given the ‘special relationship’ between the US and UK – and the particular track record of collaboration in the pharma industry – many people within and beyond the industry are trying to assess what the future will now hold. In order to try to determine this, life sciences expert Alacrita conducted a survey to gauge the views of C-suite biotech executives in the US. The results, outlined…

Keep Reading

Go to Top